These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 10475108)

  • 21. Putamen FDOPA uptake and its relationship tot cognitive functioning in PD.
    van Beilen M; Leenders KL
    J Neurol Sci; 2006 Oct; 248(1-2):68-71. PubMed ID: 16782131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
    Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic properties in functional connectivity changes and striatal dopamine deficiency in Parkinson's disease.
    Asendorf AL; Theis H; Tittgemeyer M; Timmermann L; Fink GR; Drzezga A; Eggers C; Ruppert-Junck MC; Pedrosa DJ; Hoenig MC; van Eimeren T
    Hum Brain Mapp; 2024 Jul; 45(10):e26776. PubMed ID: 38958131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
    Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
    Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.
    Wang J; Zuo CT; Jiang YP; Guan YH; Chen ZP; Xiang JD; Yang LQ; Ding ZT; Wu JJ; Su HL
    J Neurol; 2007 Feb; 254(2):185-90. PubMed ID: 17334953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
    Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
    J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
    Burn DJ; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
    Otsuka M; Ichiya Y; Kuwabara Y; Hosokawa S; Sasaki M; Yoshida T; Fukumura T; Masuda K; Kato M
    J Neurol Sci; 1996 Mar; 136(1-2):169-73. PubMed ID: 8815166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
    Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild cognitive impairment in Parkinson's disease is associated with decreased P300 amplitude and reduced putamen volume.
    Hünerli D; Emek-Savaş DD; Çavuşoğlu B; Dönmez Çolakoğlu B; Ada E; Yener GG
    Clin Neurophysiol; 2019 Aug; 130(8):1208-1217. PubMed ID: 31163365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.
    Cheesman AL; Barker RA; Lewis SJ; Robbins TW; Owen AM; Brooks DJ
    J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1204-10. PubMed ID: 16107352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.